相关实验视频

Updated: Jan 13, 2026

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Establishment of Hepatocarcinoma in BALB/c-nu Mice and Investigation of the Therapeutic Effect of the Sanleng Jiashen Formula

Published on: January 26, 2024

金色化物Rh₃通过调节FGFR4-STAT3-YAP信号通路来增强肝细胞癌中regorafenib的疗效

Youngsic Jeon¹, Hyukjoon Kwon¹, Taek Chung²

¹Institute of Natural Products, Korea Institute of Science and Technology, the Republic of Korea.

Biochemical pharmacology

|January 7, 2026

概括

金色化物Rh3与regorafenib相结合显示出治疗肝癌 (HCC) 的前景. 这种组合疗法向关键的癌症生长途径,降低细胞活力和调高细胞死亡信号.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

越来越多的人对结合性癌症疗法感兴趣,以提高疗效和安全.
调查人参酸的新型治疗应用,超越它们已知的免疫调节和抗氧化作用.
肝细胞癌 (HCC) 仍然是一个重大的全球健康挑战,需要创新的治疗策略.

研究的目的:

为了确定金氏化物Rh3是否增强了在肝细胞癌 (HCC) 中regorafenib的抗癌作用.
阐明基因化物Rh3和regorafenib之间协同相互作用的分子机制.
探索这种组合作为HCC新治疗方法的潜力.

主要方法:

使用酶活性检测分析细胞信号通路的蛋白质基因分析.
评估HCC细胞活力和亡标志物的评估.
评估关键蛋白质酸化,核转位和转录活性.

主要成果:

与单独使用的任何一种药物相比,与regorafenib结合的金色化物Rh3显著降低了HCC细胞活力.
组合疗法减弱了信号转换器和转录激活器3 (STAT3) 的酸化,并且禁用了FGFR4和JAK2.
观察到TEAD-依赖转录的抑制没有促进YAP核积累.

结论:

在HCC中,金氏酸Rh3和雷戈拉费尼的协同作用是由FGFR4/JAK2/STAT3信号轴的抑制介导的.
对YAP-TEAD转录活性的减弱有助于观察到的抗癌效应.
这种组合需要进一步的临床研究来治疗肝细胞癌.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.组合疗法是一种联合疗法.人参化物 Rh ((3))肝细胞癌是肝细胞癌.雷戈拉费尼布的使用情况

更多相关视频

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

相关概念视频

Receptor Downregulation in MVBs

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

PI3K/mTOR/AKT Signaling Pathway

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...